159 related articles for article (PubMed ID: 20657551)
21. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
[TBL] [Abstract][Full Text] [Related]
22. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
23. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
24. Current perspective - trastuzumab.
Hall PS; Cameron DA
Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
[TBL] [Abstract][Full Text] [Related]
25. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
Kulkarni S; Hicks DG
Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
27. Her2 and trastuzumab in breast cancer.
Horton J
Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040
[No Abstract] [Full Text] [Related]
28. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R
Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563
[TBL] [Abstract][Full Text] [Related]
29. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M; Procter M; McCaskill-Stevens W; de Azambuja E; Dafni U; Rueschoff J; Jordan B; Dolci S; Abramovitz M; Stoss O; Viale G; Gelber RD; Piccart-Gebhart M; Leyland-Jones B
J Clin Oncol; 2009 Jun; 27(18):2962-9. PubMed ID: 19364966
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
31. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
32. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
33. Resistance to trastuzumab: a necessary evil or a temporary challenge?
Cardoso F; Piccart MJ; Durbecq V; Di Leo A
Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
35. [The clinical relevance of the overexpression of HER-2 in breast cancer].
Khosravi Shahi P; Pérez Manga G
An Med Interna; 2006 Mar; 23(3):103-4. PubMed ID: 16737428
[No Abstract] [Full Text] [Related]
36. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
37. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
38. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
39. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab and breast cancer: developments and current status.
Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
